GluBio Therapeutics
PrivateLast Round
Strategic
Feb 11, 2026
Total Funding Raised
$122M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
GluBio Therapeutics operates in Healthcare & Life Sciences and is based in San Diego, California. Its latest recorded funding round was a Strategic round in February 2026.
GluBio Therapeutics is a biotechnology company that discovers and develops innovative molecular glue-targeted protein degradation drugs to address unmet medical needs in oncology, autoimmune diseases, and genetic disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
GluBio Therapeutics Comparables
Compare GluBio Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Plexium | 88% | |
| SEED Therapeutics | 84% | |
| Neomorph | 84% |
For institutional investors. Book with your work email.
GluBio Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Strategic | Feb 11, 2026 | ||||
| Series A Extension | Aug 1, 2022 | ||||
| Series A | Feb 28, 2022 | ||||
| Seed | Feb 1, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
GluBio Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Hillhouse Investment | Series A |
| Kaitai Capital | Series A, Series A Extension, Seed |
| Legend Capital | Series A |
| E Fund Management | Series A |
| 险峰K2VC | Series A, Seed |
| Lilly Asia Ventures | Series A, Series A Extension |
| Qiming Venture Partners | Series A, Series A Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 25, 2026
Monthly visitors increased 56% MoM.
- Jan 19, 2026
Monthly visitors grew 1574% MoM, from 23 to 385.
For institutional investors. Book with your work email.
GluBio Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about GluBio Therapeutics's valuation, stock price, and market status.
Is GluBio Therapeutics a public or private company?
GluBio Therapeutics is a private company.
What is the current stock price of GluBio Therapeutics?
GluBio Therapeutics is a private company, so its shares have no public market price. Caplight tracks GluBio Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is GluBio Therapeutics worth (valuation)?
Valuation information for GluBio Therapeutics is not publicly available.
Can I buy GluBio Therapeutics stock?
GluBio Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was GluBio Therapeutics's last funding round?
GluBio Therapeutics's most recent funding round was Strategic on February 11, 2026.
Who are the main investors in GluBio Therapeutics?
Key investors in GluBio Therapeutics include Hillhouse Investment, Qiming Venture Partners.
Will GluBio Therapeutics IPO soon?
No public IPO plans have been announced for GluBio Therapeutics.
How can I track GluBio Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in GluBio Therapeutics's shares on secondary markets.